Used in pharmaceutical research as a potent inhibitor of tyrosine kinases, particularly involved in signaling pathways related to cancer cell proliferation and survival. Shows promise in targeted therapies for solid tumors, especially non-small cell lung cancer and other epithelial cancers. Its structure enables high selectivity for mutant forms of EGFR, including T790M and C797S variants, making it valuable in overcoming resistance to earlier generations of kinase inhibitors. Currently investigated in preclinical and clinical studies for efficacy, pharmacokinetics, and safety in oncology.